RedHill Biopharma Ltd. ADR | Ownership
Companies that own RedHill Biopharma Ltd. ADR
683 Capital Management LLC
2,797,686
10.97%
755,032
2.38%
08/06/2018
OrbiMed Advisors LLC
564,900
2.21%
0
0.04%
06/30/2018
Menora Mivtachim Insurance Ltd.
421,000
1.65%
0
0.08%
06/30/2018
Migdal Insurance Co. Ltd. (Investment Portfolio)
396,134
1.55%
-1,190
0.06%
06/30/2018
Kepos Capital LP
218,800
0.86%
218,800
0.08%
06/30/2018
Creative Planning, Inc.
140,389
0.55%
0
0%
06/30/2018
ARK Investment Management LLC
112,648
0.44%
8,894
0.03%
06/30/2018
New York Life Investment Management LLC
71,267
0.28%
0
0.01%
06/30/2018
Meitav Ds Mutual Funds Ltd.
48,000
0.19%
0
0.01%
06/30/2018
Claret Asset Management Corp.
47,522
0.19%
0
0.07%
06/30/2018
| Address |
21 Ha'arba'a Street
Tel Aviv TA 64739
Israel
|
|
Employees
|
- |
| Website |
http://www.redhillbio.com |
| Updated |
07/08/2019 |
| RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill's pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs. Its late clinical-stage pipeline includes TALICIA® (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria (NTM) infections; BEKINDA® (RHB-102) for acute gastroenteritis and gastritis and IBS-D; YELIVA® (ABC294640) for cholangiocarcinoma and targeting multiple other oncology, inflammatory and gastrointestinal indications; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and RHB-107, targeting cancer and inflammatory gastrointestinal diseases. |
